XML 53 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2

Business Segments (Tables)

6 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Operating and Reportable Segments

The tables below summarize information about our reportable segments.

			Three Months Ended September 30, 2022
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	252,054					$	37,219											$	289,273
Cost of sales			113,533						14,731												128,264
Gross profit			138,521						22,488												161,009
Advertising and marketing			39,316						4,503												43,819
Contribution margin			$	99,205					$	17,985											117,190
Other operating expenses																					32,806
Operating income																					$	84,384
* Intersegment revenues of $1.1 million were eliminated from the North American OTC Healthcare segment.

			Six Months Ended September 30, 2022
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	494,572					$	71,760											$	566,332
Cost of sales			216,454						28,750												245,204
Gross profit			278,118						43,010												321,128
Advertising and marketing			74,728						9,042												83,770
Contribution margin			$	203,390					$	33,968											237,358
Other operating expenses																					65,960
Operating income																					$	171,398
* Intersegment revenues of $1.7 million were eliminated from the North American OTC Healthcare segment.

			Three Months Ended September 30, 2021
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	251,728					$	24,497											$	276,225
Cost of sales			108,623						9,890												118,513
Gross profit			143,105						14,607												157,712
Advertising and marketing			36,493						4,237												40,730
Contribution margin			$	106,612					$	10,370											116,982
Other operating expenses																					38,424
Operating income																					$	78,558
* Intersegment revenues of $0.7 million were eliminated from the North American OTC Healthcare segment.

			Six Months Ended September 30, 2021
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	494,121					$	51,285											$	545,406
Cost of sales			208,027						20,655												228,682
Gross profit			286,094						30,630												316,724
Advertising and marketing			71,723						8,446												80,169
Contribution margin			$	214,371					$	22,184											236,555
Other operating expenses																					66,655
Operating income																					$	169,900
* Intersegment revenues of $1.7 million were eliminated from the North American OTC Healthcare segment.

Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.

			Three Months Ended September 30, 2022
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	32,750					$	541											$	33,291
Cough & Cold			24,058						7,168												31,226
Women's Health			59,379						4,745												64,124
Gastrointestinal			41,272						16,037												57,309
Eye & Ear Care			37,961						4,734												42,695
Dermatologicals			32,872						902												33,774
Oral Care			21,251						3,080												24,331
Other OTC			2,511						12												2,523
Total segment revenues			$	252,054					$	37,219											$	289,273

			Six Months Ended September 30, 2022
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	60,547					$	994											$	61,541
Cough & Cold			45,650						13,439												59,089
Women's Health			120,563						9,612												130,175
Gastrointestinal			81,339						30,064												111,403
Eye & Ear Care			76,572						9,470												86,042
Dermatologicals			62,327						1,908												64,235
Oral Care			42,226						6,250												48,476
Other OTC			5,348						23												5,371
Total segment revenues			$	494,572					$	71,760											$	566,332

			Three Months Ended September 30, 2021
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	29,943					$	396											$	30,339
Cough & Cold			23,022						5,006												28,028
Women's Health			65,020						3,345												68,365
Gastrointestinal			37,964						8,641												46,605
Eye & Ear Care			37,818						2,988												40,806
Dermatologicals			32,365						839												33,204
Oral Care			22,893						3,278												26,171
Other OTC			2,703						4												2,707
Total segment revenues			$	251,728					$	24,497											$	276,225

			Six Months Ended September 30, 2021
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	62,764					$	802											$	63,566
Cough & Cold			37,067						9,853												46,920
Women's Health			128,268						7,289												135,557
Gastrointestinal			80,330						18,845												99,175
Eye & Ear Care			73,805						6,446												80,251
Dermatologicals			63,515						1,778												65,293
Oral Care			43,860						6,267												50,127
Other OTC			4,512						5												4,517
Total segment revenues			$	494,121					$	51,285											$	545,406

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration